Quarterly report · Q2
2590.TEDINET S100RSF9
Period2023-01-21 → 2023-07-20
Filed2023-09-01
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥101.7bn | 2023-01-21 → 2023-07-20 | Cons. | Net sales |
| Revenue | ¥160.1bn | 2022-01-21 → 2023-01-20 | Cons. | Net sales (5-year summary) |
| Revenue | ¥79.8bn | 2022-01-21 → 2022-07-20 | Cons. | Net sales |
| Operating income | ¥2.5bn | 2023-01-21 → 2023-07-20 | Cons. | Operating income |
| Operating income | ¥723m | 2022-01-21 → 2022-07-20 | Cons. | Operating income |
| Ordinary income | ¥1.8bn | 2023-01-21 → 2023-07-20 | Cons. | Ordinary income |
| Ordinary income | ¥591m | 2022-01-21 → 2023-01-20 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥461m | 2022-01-21 → 2022-07-20 | Cons. | Ordinary income |
| Profit before tax | ¥4.1bn | 2023-01-21 → 2023-07-20 | Cons. | Income before income taxes |
| Profit before tax | ¥351m | 2022-01-21 → 2022-07-20 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.3bn | 2023-01-21 → 2023-07-20 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥507m | 2022-01-21 → 2023-01-20 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥869m | 2022-01-21 → 2022-07-20 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.4bn | 2023-01-21 → 2023-07-20 | Cons. | Profit loss |
| Net income | −¥909m | 2022-01-21 → 2022-07-20 | Cons. | Profit loss |
| Total assets | ¥182.1bn | at 2023-07-20 | Cons. | Assets |
| Total assets | ¥164.2bn | at 2023-01-20 | Cons. | Assets |
| Total assets | ¥170.3bn | at 2022-07-20 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥94.3bn | at 2023-07-20 | Cons. | Liabilities |
| Total liabilities | ¥80.1bn | at 2023-01-20 | Cons. | Liabilities |
| Net assets / equity | ¥87.8bn | at 2023-07-20 | Cons. | Net assets |
| Net assets / equity | ¥84.1bn | at 2023-01-20 | Cons. | Net assets |
| Net assets / equity | ¥84.3bn | at 2022-07-20 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥30.0bn | at 2023-07-20 | Cons. | Cash and deposits |
| Cash and deposits | ¥27.2bn | at 2023-01-20 | Cons. | Cash and deposits |
| Cash & equivalents | ¥33.0bn | at 2023-07-20 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥29.2bn | at 2023-01-20 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥28.8bn | at 2022-07-20 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥30.1bn | at 2022-01-20d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥2.7bn | 2023-01-21 → 2023-07-20 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥5.1bn | 2022-01-21 → 2023-01-20 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥423m | 2022-01-21 → 2022-07-20 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥1.4bn | 2023-01-21 → 2023-07-20 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥5.0bn | 2022-01-21 → 2023-01-20 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.8bn | 2022-01-21 → 2022-07-20 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥50m | 2023-01-21 → 2023-07-20 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.1bn | 2022-01-21 → 2023-01-20 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.7bn | 2022-01-21 → 2022-07-20 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥149.29 | 2023-01-21 → 2023-07-20 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥168.12 | 2023-04-21 → 2023-07-20d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-32.4 | 2022-01-21 → 2023-01-20 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-55.54 | 2022-01-21 → 2022-07-20 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-0.77 | 2022-04-21 → 2022-07-20d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 47.2% | at 2023-07-20 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.9% | at 2023-01-20 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 49.3% | at 2022-07-20 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 46
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-01-21 → 2023-07-20 | −¥204m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-21 → 2023-07-20 | −¥204m |
| Reconciling Itemsreconciling | segment profit | 2023-01-21 → 2023-07-20 | −¥502m |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | revenue | 2023-01-21 → 2023-07-20 | ¥74.3bn |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | revenue external | 2023-01-21 → 2023-07-20 | ¥74.2bn |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | revenue intersegment | 2023-01-21 → 2023-07-20 | ¥19m |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | segment profit | 2023-01-21 → 2023-07-20 | ¥1.8bn |
| jpcrp040300-q2r_E00424-000Dy Do Pharmareportable segment | segment profit | 2023-01-21 → 2023-07-20 | −¥296m |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | revenue | 2023-01-21 → 2023-07-20 | ¥10.8bn |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | revenue external | 2023-01-21 → 2023-07-20 | ¥10.8bn |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | revenue intersegment | 2023-01-21 → 2023-07-20 | ¥3m |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | segment profit | 2023-01-21 → 2023-07-20 | ¥776m |
| jpcrp040300-q2r_E00424-000International Beverage Businessreportable segment | revenue | 2023-01-21 → 2023-07-20 | ¥10.5bn |
| jpcrp040300-q2r_E00424-000International Beverage Businessreportable segment | revenue external | 2023-01-21 → 2023-07-20 | ¥10.5bn |
| jpcrp040300-q2r_E00424-000International Beverage Businessreportable segment | segment profit | 2023-01-21 → 2023-07-20 | ¥462m |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | revenue | 2023-01-21 → 2023-07-20 | ¥6.4bn |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | revenue external | 2023-01-21 → 2023-07-20 | ¥6.2bn |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | revenue intersegment | 2023-01-21 → 2023-07-20 | ¥180m |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | segment profit | 2023-01-21 → 2023-07-20 | ¥239m |
| —segment total | revenue | 2023-01-21 → 2023-07-20 | ¥102.0bn |
| —segment total | revenue external | 2023-01-21 → 2023-07-20 | ¥101.7bn |
| —segment total | revenue intersegment | 2023-01-21 → 2023-07-20 | ¥204m |
| —segment total | segment profit | 2023-01-21 → 2023-07-20 | ¥3.0bn |
| Reconciling Itemsreconciling | revenue | 2022-01-21 → 2022-07-20 | −¥302m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-01-21 → 2022-07-20 | −¥302m |
| Reconciling Itemsreconciling | segment profit | 2022-01-21 → 2022-07-20 | −¥615m |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | revenue | 2022-01-21 → 2022-07-20 | ¥54.0bn |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | revenue external | 2022-01-21 → 2022-07-20 | ¥54.0bn |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | revenue intersegment | 2022-01-21 → 2022-07-20 | ¥21m |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | segment profit | 2022-01-21 → 2022-07-20 | ¥1.4bn |
| jpcrp040300-q2r_E00424-000Dy Do Pharmareportable segment | segment profit | 2022-01-21 → 2022-07-20 | −¥269m |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | revenue | 2022-01-21 → 2022-07-20 | ¥10.8bn |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | revenue external | 2022-01-21 → 2022-07-20 | ¥10.8bn |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | revenue intersegment | 2022-01-21 → 2022-07-20 | ¥4m |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | segment profit | 2022-01-21 → 2022-07-20 | ¥908m |
| jpcrp040300-q2r_E00424-000International Beverage Businessreportable segment | revenue | 2022-01-21 → 2022-07-20 | ¥9.3bn |
| jpcrp040300-q2r_E00424-000International Beverage Businessreportable segment | revenue external | 2022-01-21 → 2022-07-20 | ¥9.3bn |
| jpcrp040300-q2r_E00424-000International Beverage Businessreportable segment | segment profit | 2022-01-21 → 2022-07-20 | −¥735m |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | revenue | 2022-01-21 → 2022-07-20 | ¥6.0bn |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | revenue external | 2022-01-21 → 2022-07-20 | ¥5.7bn |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | revenue intersegment | 2022-01-21 → 2022-07-20 | ¥276m |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | segment profit | 2022-01-21 → 2022-07-20 | ¥66m |
| —segment total | revenue | 2022-01-21 → 2022-07-20 | ¥80.1bn |
| —segment total | revenue external | 2022-01-21 → 2022-07-20 | ¥79.8bn |
| —segment total | revenue intersegment | 2022-01-21 → 2022-07-20 | ¥302m |
| —segment total | segment profit | 2022-01-21 → 2022-07-20 | ¥1.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 564
| Item | Context | Value | Unit |
|---|---|---|---|
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | 302000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -302000000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00424-000DomesticBeverageBusinessReportableSegmentsMember | 54001000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00424-000InternationalBeverageBusinessReportableSegmentsMember | 9281000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00424-000PharmaceuticalRelatedBusinessReportableSegmentsMember | 5956000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00424-000FoodBusinessReportableSegmentsMember | 10844000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00424-000DyDoPharmaReportableSegmentsMember | － | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 80083000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -302000000 | JPY |
| Net sales | Prior1YTDDuration | 79781000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00424-000DomesticBeverageBusinessReportableSegmentsMember | 1368000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00424-000InternationalBeverageBusinessReportableSegmentsMember | -735000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00424-000PharmaceuticalRelatedBusinessReportableSegmentsMember | 66000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00424-000FoodBusinessReportableSegmentsMember | 908000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00424-000DyDoPharmaReportableSegmentsMember | -269000000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | 1339000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -615000000 | JPY |
| Operating income | Prior1YTDDuration | 723000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00424-000DomesticBeverageBusinessReportableSegmentsMember | 74234000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00424-000InternationalBeverageBusinessReportableSegmentsMember | 10459000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00424-000PharmaceuticalRelatedBusinessReportableSegmentsMember | 6206000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00424-000FoodBusinessReportableSegmentsMember | 10846000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00424-000DyDoPharmaReportableSegmentsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 101746000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 101746000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00424-000DomesticBeverageBusinessReportableSegmentsMember | 19000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00424-000InternationalBeverageBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00424-000PharmaceuticalRelatedBusinessReportableSegmentsMember | 180000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00424-000FoodBusinessReportableSegmentsMember | 3000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00424-000DyDoPharmaReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 204000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -204000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00424-000DomesticBeverageBusinessReportableSegmentsMember | 74253000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00424-000InternationalBeverageBusinessReportableSegmentsMember | 10459000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00424-000PharmaceuticalRelatedBusinessReportableSegmentsMember | 6386000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00424-000FoodBusinessReportableSegmentsMember | 10850000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00424-000DyDoPharmaReportableSegmentsMember | － | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 101950000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -204000000 | JPY |
| Net sales | CurrentYTDDuration | 101746000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00424-000DomesticBeverageBusinessReportableSegmentsMember | 1847000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00424-000InternationalBeverageBusinessReportableSegmentsMember | 462000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00424-000PharmaceuticalRelatedBusinessReportableSegmentsMember | 239000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00424-000FoodBusinessReportableSegmentsMember | 776000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00424-000DyDoPharmaReportableSegmentsMember | -296000000 | JPY |
| Operating income | CurrentYTDDuration_ReportableSegmentsMember | 3029000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -502000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |